ATON SA (ALTAO.PA) Stock Price & Overview
EPA:ALTAO • FR0004153930
Current stock price
The current stock price of ALTAO.PA is 0.006 EUR. Today ALTAO.PA is up by 3.45%. In the past year, price decreased by -38.78%.
ALTAO.PA Key Statistics
- Market Cap
- 4.969M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
ALTAO.PA Stock Performance
ALTAO.PA Stock Chart
ALTAO.PA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ALTAO.PA. When comparing the yearly performance of all stocks, ALTAO.PA is a bad performer in the overall market: 92.85% of all stocks are doing better.
ALTAO.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALTAO.PA. ALTAO.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALTAO.PA Earnings
ALTAO.PA Forecast & Estimates
ALTAO.PA Groups
Sector & Classification
ALTAO.PA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.58% | ||
| ROE | -265.3% | ||
| Debt/Equity | 5.62 |
ALTAO.PA Ownership
ALTAO.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 29.78 | 44.565B | ||
| ARGX | ARGENX SE | 29.75 | 44.006B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.431B | ||
| 2X1 | ABIVAX SA | N/A | 8.246B | ||
| ABVX | ABIVAX SA | N/A | 7.961B | ||
| GLPG | GALAPAGOS NV | N/A | 1.638B | ||
| GXE | GALAPAGOS NV | N/A | 1.612B | ||
| NANO | NANOBIOTIX | N/A | 1.342B | ||
| PHGN | PHARMING GROUP NV | 48.29 | 1.054B | ||
| PHARM | PHARMING GROUP NV | 48.34 | 1.05B | ||
| IVA | INVENTIVA SA | N/A | 1.004B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 996.493M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 991.483M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALTAO.PA
Company Profile
Aton SA operates as a biopharmaceutical company, which engages in the research and development of targets and therapies for the treatment of proliferative diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 9 full-time employees. The company went IPO on 2007-12-17. The company specializes in the research and development of drugs intended for cancer treatment and supplies scientific services in the protein interaction field. The firm is specialized in the research and development (R&D) of drugs to fight cancer. The company is organized in two units: Hybrigenics Pharma for internal R&D, which develops a research program aimed at such diseases as melanoma and prostate cancer; and Hybrigenics Services for commercial business, mainly engaged in protein interaction information and solutions. Hybrigenics SA’s main development program is based on inecalcitol, a vitamin D analogue, for prostate cancer treatment. The company operates through Hybrigenics Corporation and Imaxio.
Company Info
IPO: 2007-12-17
ATON SA
850 Boulevard Sebastien Brant
Illkirch-Graffenstaden GRAND EST FR
Employees: 9
Phone: 33972569499
ATON SA / ALTAO.PA FAQ
What does ATON SA do?
Aton SA operates as a biopharmaceutical company, which engages in the research and development of targets and therapies for the treatment of proliferative diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 9 full-time employees. The company went IPO on 2007-12-17. The company specializes in the research and development of drugs intended for cancer treatment and supplies scientific services in the protein interaction field. The firm is specialized in the research and development (R&D) of drugs to fight cancer. The company is organized in two units: Hybrigenics Pharma for internal R&D, which develops a research program aimed at such diseases as melanoma and prostate cancer; and Hybrigenics Services for commercial business, mainly engaged in protein interaction information and solutions. Hybrigenics SA’s main development program is based on inecalcitol, a vitamin D analogue, for prostate cancer treatment. The company operates through Hybrigenics Corporation and Imaxio.
Can you provide the latest stock price for ATON SA?
The current stock price of ALTAO.PA is 0.006 EUR. The price increased by 3.45% in the last trading session.
What is the dividend status of ATON SA?
ALTAO.PA does not pay a dividend.
How is the ChartMill rating for ATON SA?
ALTAO.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the market capitalization of ALTAO stock?
ATON SA (ALTAO.PA) has a market capitalization of 4.97M EUR. This makes ALTAO.PA a Nano Cap stock.